Psychedelics May Be Key to Effective Dementia Trea
Post# of 160
(Total Views: 215)
Posted On: 12/30/2021 5:02:05 PM
Psychedelics May Be Key to Effective Dementia Treatment
Dementia is known to affect an individual’s mental processes, leading to loss of cognitive functioning. It is typically caused by brain injury or disease and is marked by impaired reasoning, changes in personality and memory disorders. In its later stages, the disease kills off the brain cells linked to muscle control, gradually limiting the person’s ability to stand, walk and even swallow food.
Estimates from the CDC show that more than 5.7 million individuals suffer from dementia and Alzheimer’s disease, a progressive disorder that destroys memory. Projections show that this number could reach roughly 14 million in the next four decades. There exists no cure for dementia or similar disorders, including Alzheimer’s. However, researchers believe that psychedelic drugs may be a key to developing one.
Despite the disease’s growing prevalence globally, drug-development programs for dementia have yielded minimal results. Return Health CEO Dr. James Kuo states that multiple ailments cause dementia and without knowledge about what causes the disease, it’s difficult to develop a cure.
While the field of medicine has turned to genome sequencing and DNA testing to shed light on the root causes of some of these ailments, scientists still have much to learn when it comes to dementia. Return Health is using a different approach to learn more about the ailment by treating its symptoms using psychedelic drugs.
Various studies on psychedelics have found that they possess the potential to manage treatment-resistant mental conditions that share symptoms with dementia and Alzheimer’s. Dr. Albert Garcia-Romeu, an assistant professor of psychiatry and behavioral sciences at Johns Hopkins, revealed that preliminary psilocybin clinical trials had shown persisting decreases in addictive behaviors, depressed mood and anxiety. The professor explained that this suggested that the substances could have therapeutic benefits in some individuals suffering from neurodegenerative disorders that were characterized by neuronal atrophy.
Many researchers also believe that psychedelics can stop or even reverse cognitive decline by improving neuroplasticity, inducing neurogenesis and reducing neuro-inflammation.
While most studies have centered on the use of LSD, MDMA and psilocybin in treating neurodegenerative disorders and mental health conditions, Kuo and his research team plans to use DMT in their research because it has demonstrated the most effectiveness in neurogenesis. Return Health is optimistic that its evidence-based research will yield fruitful results that will revolutionize the treatment of these serious indications.
It should be noted that psychedelics such as LSD and psilocybin are still classified as Schedule I substances under the Controlled Substances Act even if entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) have shown that these substances hold plenty of potential as medicinal compounds.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Dementia is known to affect an individual’s mental processes, leading to loss of cognitive functioning. It is typically caused by brain injury or disease and is marked by impaired reasoning, changes in personality and memory disorders. In its later stages, the disease kills off the brain cells linked to muscle control, gradually limiting the person’s ability to stand, walk and even swallow food.
Estimates from the CDC show that more than 5.7 million individuals suffer from dementia and Alzheimer’s disease, a progressive disorder that destroys memory. Projections show that this number could reach roughly 14 million in the next four decades. There exists no cure for dementia or similar disorders, including Alzheimer’s. However, researchers believe that psychedelic drugs may be a key to developing one.
Despite the disease’s growing prevalence globally, drug-development programs for dementia have yielded minimal results. Return Health CEO Dr. James Kuo states that multiple ailments cause dementia and without knowledge about what causes the disease, it’s difficult to develop a cure.
While the field of medicine has turned to genome sequencing and DNA testing to shed light on the root causes of some of these ailments, scientists still have much to learn when it comes to dementia. Return Health is using a different approach to learn more about the ailment by treating its symptoms using psychedelic drugs.
Various studies on psychedelics have found that they possess the potential to manage treatment-resistant mental conditions that share symptoms with dementia and Alzheimer’s. Dr. Albert Garcia-Romeu, an assistant professor of psychiatry and behavioral sciences at Johns Hopkins, revealed that preliminary psilocybin clinical trials had shown persisting decreases in addictive behaviors, depressed mood and anxiety. The professor explained that this suggested that the substances could have therapeutic benefits in some individuals suffering from neurodegenerative disorders that were characterized by neuronal atrophy.
Many researchers also believe that psychedelics can stop or even reverse cognitive decline by improving neuroplasticity, inducing neurogenesis and reducing neuro-inflammation.
While most studies have centered on the use of LSD, MDMA and psilocybin in treating neurodegenerative disorders and mental health conditions, Kuo and his research team plans to use DMT in their research because it has demonstrated the most effectiveness in neurogenesis. Return Health is optimistic that its evidence-based research will yield fruitful results that will revolutionize the treatment of these serious indications.
It should be noted that psychedelics such as LSD and psilocybin are still classified as Schedule I substances under the Controlled Substances Act even if entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) have shown that these substances hold plenty of potential as medicinal compounds.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)Mydecine Innovations Group Inc (MYCOF) Stock Research Links
Scroll down for more posts ▼